Orgenics
Diagnostic Products for Serious and Life-threatening Conditions
Company Overview
Snapshot
Founded in January 1982, Orgenics operates with over 500 employees. The company was acquired by Alere in January 1996, marking a significant milestone in its journey.
Business overview
Orgenics develops diagnostic products designed for serious and life-threatening conditions and diseases. The company's core technology includes patented ImmunoComb products, which are rapid enzyme immunoassays for detecting antibodies or antigens in human serum or plasma. These products are known for their speed, ease of use, high sensitivity, and specificity, making them suitable for decentralized clinical laboratories, field hospitals, and remote rural areas. Orgenics serves markets across Europe, Asia, South America, the United States, and Africa, contributing to increased awareness and early detection of conditions like HIV and other infectious diseases within the Health Tech & Life Sciences sector.
Strategic signal
In August 2013, the FDA approved the first rapid test for HIV-1/2 antibodies and HIV-1 antigen. This regulatory approval validated the significance of rapid diagnostic tools in public health, signaling a growing market and acceptance for companies like Orgenics that specialize in quick, accurate, and accessible diagnostic solutions for critical conditions.
Log in to access full profile ›Company Intelligence Q&A
- When was Orgenics founded?
- Orgenics was founded in January 1982.
- What is Orgenics' primary focus?
- Orgenics focuses on developing accurate and safe diagnostic products for serious and life-threatening conditions and diseases.
- What is the status of Orgenics?
- Orgenics was acquired by Alere in January 1996 and is currently inactive.
- What kind of products does Orgenics offer?
- Orgenics offers patented ImmunoComb products, which are rapid enzyme immunoassays for detecting antibodies or antigens in human serum or plasma.
- What was a notable regulatory approval related to diagnostic products?
- In August 2013, the FDA approved the first rapid test for HIV-1/2 antibodies and HIV-1 antigen, which is relevant to the diagnostic field Orgenics operates in.